

## Study Initiation Monitoring site visit

2R2 SOP12\_06Jul2020

Title	Study Initiation Monitoring Site Visit
SOP Code	2R2 SOP12_06Jul2020
Effective Date	06 July 2020

One study initiation monitoring site visit should





**APPENDIX 1**

**Example of an agenda/schedule and training points for visit**

*[include dates & times, if the site has several clinics to be visited a list of the times & dates for each clinic visit should be included. The order of the agenda will be dependent upon availability of staff and timing of visit]*

Meet with the site investigator & study coordinator if applicable

- Review administrative
- Review questions/issues at site
- Discuss primary objective of visit

Review essential documents, Master binder (regulatory review as required)

Facilities visit (research office, clinics, radiology (if applicable), Laboratory and PK facilities, study medications storage and dispensing facilities)

Presentation of the overview of the study

CRFs and SOP training

Training on study medication blinding and dispensing in clinics

Any other topics, issues, questions can be added to the agenda

Summary meeting (findings, recommendations, next step, etc)

**TRAINING POINTS**

**Protocol review & questions**

Primary & Secondary outcomes

**Review Site Start-up Procedures & Requirements**

Review Good Clinical Practice  
Master binder & essential documents

**Screening & recruitment procedures for potential patients**

Screening - Inclusion & exclusion criteria  
Inform consent/assent/parental  
Data collection – case report form (CRF) & website  
Contact information (identification form)  
Randomization on website & Manual randomization

**Follow-up during treatment**

Medical examination and investigations needed during follow-up  
Data collection – case report form (CRF) & website  
Maintenance of contact information

Compliance, Adverse events, Other medications

### **Adverse event management & reporting**

Data collection – case report form (CRF) & website

### **Follow-up post treatment**

Screening for active TB

Maintenance of contact information

### **End of treatment**

Data collection – case report form (CRF) & website

### **Follow-up post treatment**

Data collection – case report form (CRF) & website

### **Active TB management & reporting**

Data collection – case report form (CRF) & website

### **Death management & reporting**

Data collection – case report form (CRF) & website

### **End of follow-up post treatment**

Data collection – case report form (CRF) & website

### **PK sub-study**

Population, blood collection, storage & shipping

Data collection – case report form (CRF) & website

### **Summary & next steps**

### **RESOURCES**

1. Resources/procedures: study medication blinding and storage, laboratory testing, medications, dispensing, internet access
2. Facility tour (research room, clinic, pharmacy, Lab, CXR if applicable)

**APPENDIX 2 - Summary of site initiation training session for <Name of the site>**

**SITE INITIATION TRAINING**

**Task and supportive documents**

**Action**







**APPENDIX 4 - Master Binder review - Essential documents for the study at <Name of the site>**





**Study Initiation Monitoring site visit**

2R2 SOP12\_06Jul2020

APPENDIX 6

MONITORING SITE VISIT LOG

**2R2: Higher dose Rifampin for 2 months vs Standard dose Rifampin for Latent TB: a 3-arm randomized trial.**

Site name:

Site investigator:

Study Coordinator:

Site Visit Date		Type of monitoring visit	Names/ Signatures	
From	To		Monitor	Site Personnel